Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: Clin Cancer Res. 2017 Feb 6;23(14):3552–3556. doi: 10.1158/1078-0432.CCR-16-2064

Table 1. Patient cohorts and Drug Escalation Criteria.

Cohorts Pralatrexate Dose (IV) Bexarotene Dosea (PO)
Cohort 1 15 mg/m2 150 mg/m2
Cohort 2a 15 mg/m2 300 mg/m2
Cohort 2b 10 mg/m2 150 mg/m2
Cohort 3 10 mg/m2 300 mg/m2
a

Dose of bexarotene determined by guidelines per package insert.